Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes. METHODS/PRINCIPAL FINDINGS: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of 11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49-0.88) for cancer mortality, 0.67 (0.53-0.85) for all-cancer incidence, 0.68 (0.53-0.88) for colorectal cancer (n = 6), 0.20 (0.07-0.59) for hepatocellular cancer (n = 4), 0.67 (0.45-0.99) for lung cancer (n = 3). CONCLUSION/SIGNIFICANCE: The use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“All the procedures were in accordance with the guidelines for the Quality of Reporting of Meta-analyses [24], the meta-analysis of observational studies in epidemiology [25] and the PRISMA statement [26].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“In light of the fact that cancer is the second and diabetes the twelfth leading cause of death worldwide [59] and that the number of people with diabetes is”
Background
Cited by
Items 401–500 of 580
Szemerédi, N., Schelz, Z., Horvath, D. A., Rácz, B., Szatmári, A. G., Muddather, H. F., Bózsity, N., Zupkó, I., & Spengler, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070877 · Cited by 9
“It was suggested that the use of metformin in patients with type 2 diabetes decreases the incidence of several cancers, such as colorectal, lung, liver, breast, etc. [10].”
BackgroundMiniature Short Hairpin RNA Screens to Characterize Antiproliferative Drugs
Kittanakom, S., Arnoldo, A., Brown, K. R., Wallace, I. M., Kunavisarut, T., Torti, D., Heisler, L. E., Surendra, A., Moffat, J., Giaever, G. N., et al. (2013) · G3 Genes Genomes Genetics · doi:10.1534/g3.113.006437 · Cited by 7
“Recent interest in the use of metformin as a cancer chemotherapeutic was sparked by a meta-analysis of patients with diabetes that demonstrated a statistically robust decrease of several diverse cancers in those patients taking metformin (Noto et al. 2012).”
BackgroundShen, Q., Zhang, C., Jiang, X., Li, J., Liu, F., Zhang, X., En, G., & Pang, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009700 · Cited by 8
“(40) believe that taking metformin can reduce the risk of cancer in patients with diabetes, but there is no statistical significance in the study of pancreatic cancer (cited 399 times, most cited in PLOS ONE).”
BackgroundReverse cardio-oncology: A budding concept
Satpathy, C., Mishra, T. K., Singh, S., & Jha, A. K. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.09.004 · Cited by 11
Does metabolic syndrome or its components associate with prostate cancer when diagnosed on biopsy?
Telli, O., Sarıcı, H., Ekıcı, M., Özgür, B. C., Doluoğlu, Ö. G., Eroğlu, M., & Telli, T. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014560158 · Cited by 7
“This could be an important confounding variable, since metformin has been associated with a lower risk of cancer [Libby et al. 2009; Noto et al. 2012].”
BackgroundMetformin and other biguanides: pharmacology and therapeutic usage
Samson, S. L., & Garber, A. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch43 · Cited by 9
Quels bénéfices antitumoraux attendre de la metformine ?
Beck, E., & Scheen, A. J. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.02.009 · Cited by 8
van Hattum, J. W., de Ruiter, B. M., Oddens, J. R., de Reijke, T. M., Wilmink, J. W., & Molenaar, R. J. (2022) · Bladder Cancer · doi:10.3233/blc-211653 · Cited by 6
“Existing reviews about metformin and cancer incidence have focussed either on organ sites other than the bladder or do not differentiate between different cancer types [52, 53].”
Electroporation enhances cell death in 3D scaffold-based MDA-MB-231 cells treated with metformin
Sahu, P., Camarillo, I. G., Dettin, M., Zamuner, A., Conconi, M. T., Barozzi, M., Giri, P., Sundararajan, R., & Sieni, E. (2024) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2024.108734 · Cited by 6
The Role of Diabetes and Diabetes Treatments in Colorectal Cancer Mortality, Incidence, and Survival
Campbell, P. T. (2012) · Current Nutrition Reports · doi:10.1007/s13668-012-0034-y · Cited by 6
Analyses of Biguanides and Related Compounds in Biological and Environmental Samples by HPLC
Ali, I., Hussain, I., Sanagi, M. M., Ibrahim, W. A. W., & Aboul-Enein, H. Y. (2014) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2014.940803 · Cited by 6
Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial
Dalman, R. L., Lü, Y., Mahaffey, K. W., Chase, A. J., Stern, J. R., & Chang, R. W. (2020) · Vascular and Endovascular Review · doi:10.15420/ver.2020.03 · Cited by 6
“The influence of metformin on cancer is somewhat more controversial, with meta-analyses citing both salutary and indeterminate effects, leading to the initiation of multiple clinical trials of metformin in antioncologic applications, in patients with and without diabetes.(62,63) Ample experience in cancer-related appl…”
BackgroundWhat every dentist should know about metformin, diabetes, and cancer.
Frykenberg, M. R. A., Schneider, A., & Bashirelahi, N. (2015) · PubMed · Cited by 6
Receptor for advanced glycation end as drug targets in diabetes-induced skin lesion.
Chen, X., Tang, W., Lin, W., Liu, Z., Lu, X., Zhang, B., Ye, F., Liu, Z., Zou, J., & Liao, W. (2017) · Europe PMC (PubMed Central) · Cited by 7
Metformin in Oncology – How Far Is Its Repurposing as an Anticancer Drug?
Pácal, L., & Kaňková, K. (2020) · Klinicka onkologie · doi:10.14735/amko2020107 · Cited by 6
“Since then, many analyses have been performed; substantial epidemiological evidence shows that metformin use is associated with reduced risk of many types of cancers, including colorectal, pancreatic, liver and others [26].”
BackgroundMetformin and everolimus: A promising combination for neuroendocrine tumors treatment
Vitali, E., Boemi, I., Piccini, S., Tarantola, G., Zerbi, A., Smiroldo, V., Lavezzi, E., Spada, A., Mantovani, G., & Lania, A. G. (2020) · Endocrine Abstracts · doi:10.1530/endoabs.70.aep724 · Cited by 6
Chemoprevention of Colorectal Cancer—With Emphasis on Low-Dose Aspirin and Anticoagulants
Agustsson, A. S., & Bjornsson, E. S. (2025) · Pharmaceuticals · doi:10.3390/ph18060811 · Cited by 5
Obesity, type 2 diabetes and cancers of the digestive system
Cernea, S., Crișan, D., Lăcătușu, C.-M., Zaharia, O., & Gancheva, S. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.02.003 · Cited by 5
Hsu, Y., Hsu, C. Y., & Kao, Y. (2023) · Current Oncology · doi:10.3390/curroncol30040298 · Cited by 4
CADD Approaches in Anticancer Drug Discovery
Biswas, A., & Jayaprakash, V. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-1316-9_12 · Cited by 6
Al‐Odat, O. S., Nelson, E., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Desai, D. H., & Pandey, M. K. (2024) · Cancers · doi:10.3390/cancers16132381 · Cited by 6
Body Mass Index and Breast Cancer Risk: A Retrospective Multi-Institutional Analysis in Saudi Arabia
Rudat, V., Birido, N., Tuwaijri, S., & Al-Abbadi, M. A. (2013) · Advances in Breast Cancer Research · doi:10.4236/abcr.2013.21002 · Cited by 5
“Recent studies have shown that met formin significantly reduces breast cancer incidence [26-28].”
BackgroundToomey, P. G., Teta, A. F., Patel, K. D., Downs, D. J., Luberice, K., Ross, S. B., & Rosemurgy, A. S. (2017) · International Journal of Surgery Oncology · doi:10.1097/ij9.0000000000000015 · Cited by 5
“Recently, with the availability of long-term data, the use of metformin for patients with diabetes has been found to be associated with a decreased risk for any cancer([17]).”
BackgroundThompson, M. D., Lubet, R. A., McCormick, D. L., Clapper, M. L., Bode, A. M., Juliana, M. M., Moeinpour, F. L., & Grubbs, C. J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6632 · Cited by 6
“As a result of its relatively low toxicity and its ability to alter energy metabolism pathways that are important for neoplastic growth, metformin has been the subject of numerous studies as a potential cancer chemopreventive and therapeutic agent (1,2,6).”
BackgroundGan, X., Cao, C. Q., He, Y., Hu, X., Peng, X., & Su, Y. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220329113434 · Cited by 5
Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s392051 · Cited by 6
Hussain, I., Ali, I., Rahman, H., & Ghani, S. S. (2017) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2017.1334216 · Cited by 5
Purshouse, K. R., & Protheroe, A. S. (2019) · Therapeutic Advances in Urology · doi:10.1177/1756287218820804 · Cited by 5
Chen, X., Li, C., Chen, W., Lin, S., Yi, X., Lin, Q., Xu, H., & Wang, D. (2021) · Journal of Oncology · doi:10.1155/2021/2265475 · Cited by 5
“Accumulating studies have discovered that the use of metformin can significantly reduce the development of various tumors in diabetic patients [9, 10].”
BackgroundDrug Repositioning for Ovarian Cancer Treatment: An Update
Cavalluzzi, M. M., Viale, M., Rotondo, N. P., Ferraro, V., & Lentini, G. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206282904240122063914 · Cited by 5
Pharmacology and safe prescribing of metformin
Apampa, B. (2012) · Nurse Prescribing · doi:10.12968/npre.2012.10.12.597 · Cited by 8
Leitão, M. M., & Barakat, R. R. (2013) · Springer eBooks · doi:10.1007/978-3-642-38983-2_19 · Cited by 5
Huang, W., Erickson, S. R., Hansen, R. A., & Wu, C. (2016) · Medicine · doi:10.1097/md.0000000000003909 · Cited by 5
“Respondents who answered no to this question were defined as nonregular aspirin users.”
BackgroundBrown, K. A., Andreopoulou, E., & Andreopoulou, P. (2020) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2020.16.1.17 · Cited by 6
“Meta-analyses have examined the role of metformin in the primary prevention of cancer, demonstrating that it significantly reduces overall cancer incidence, but the findings were inconsistent for tumor types.(94,95)”
BackgroundDawn of a new era of diabeto‐oncology
Noto, H. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13204 · Cited by 5
Self-citationMalignancy incidences by glycemic control among diabetic patients
Kobayashi, D., Kuriyama, N., Hirano, K., Takahashi, O., & Noto, H. (2018) · Endocrine Connections · doi:10.1530/ec-18-0355 · Cited by 4
Self-citationA novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres
Roh, T. H., Lee, J.-H., Kim, S. J., Shim, J., Park, J., Yoon, S., Teo, W., Kim, S. H., Chang, J. H., & Kang, S. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03903-7 · Cited by 4
Everatt, R., Kuzmickienė, I., Brasiūnienė, B., Vincerževskienė, I., Intaitė, B., Cicėnas, S., & Lisauskienė, I. (2025) · BMC Cancer · doi:10.1186/s12885-024-13273-8 · Cited by 4
“…confounding statin, antidiabetic and antithrombotic medicines use (dates of prescription and purchase, dose, strength and amount of the drug) was also extracted from the NHIF database, because previous studies have suggested that these drugs could reduce mortality in patients with cancer [31–33].”
Ohnishi, H., Saitoh, S., Akasaka, H., Furukawa, T., Mori, M., & Miura, T. (2015) · Diabetology International · doi:10.1007/s13340-015-0232-0 · Cited by 4
Lee, J. H., & Kim, T. I. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0198-x · Cited by 6
Drug Repurposing to Circumvent Chemotherapy Resistance in Brain Tumours
Hill, R., Murray, S. A., Maherally, Z., Higgins, S. C., & Pilkington, G. J. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46505-0_6 · Cited by 4
Merrick, G. S., Bennett, A., Couture, T., Butler, W. M., Galbreath, R. W., & Adamovich, E. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000174 · Cited by 5
Preventive and (Neo)Adjuvant Therapeutic Effects of Metformin on Cancer
Jiao, Y., Wang, X., & Luo, Z. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91291 · Cited by 4
Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma
Ono, M., Fujita, K., Kobayashi, K., & Masaki, T. (2023) · Hepatology Research · doi:10.1111/hepr.13912 · Cited by 4
Schweitzer, N., & Vogel, A. (2013) · InTech eBooks · doi:10.5772/55908 · Cited by 4
“The results of several retrospective studies and meta-analyses suggest a preventive role of metformin in diabetic patients, while sulfonylurea drugs and insulin seem to facilitate the development of cirrhosis [38-40].”
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence
Tuccori, M., Convertino, I., Galiulo, M. T., Marino, A., Capogrosso-Sansone, A., & Blandizzi, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361401 · Cited by 5
Genotoxic properties of hypoglycemic drugs (systematic review)
Eremina, N. V., Жанатаев, А. К., Lisitsyn, A. A., & Durnev, A. D. (2021) · Ecological genetics · doi:10.17816/ecogen70691 · Cited by 4
Metformin and Infections: What Is the Next Step in This Decades-Long Story?
Goto, M., & Perencevich, E. N. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac903 · Cited by 4
Sekino, N., Kano, M., Murakami, K., Toyozumi, T., Hayano, K., Ohira, G., & Matsubara, H. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2756 · Cited by 3
“Metformin effectively reduces the risk of tumor development in many types of cancer, including ESCC (17).”
BackgroundRisk of Incident Cancer in Veterans with Diabetes Who Use Metformin Versus Sulfonylureas
Abdallah, M. M., de Oliveira, B. D., DuMontier, C., Orkaby, A. R., Nussbaum, L. S., Gaziano, J. M., Djoussé, L., GAGNON, D. R., Cho, K., Preis, S. R., et al. (2024) · Journal of Cancer Prevention · doi:10.15430/jcp.24.012 · Cited by 3
Kubo, H., Ohgi, K., Otsuka, S., Okawa, Y., Ashida, R., Yamada, M., Kato, Y., Dei, H., Uesaka, K., Notsu, A., et al. (2025) · Annals of Surgery Open · doi:10.1097/as9.0000000000000597 · Cited by 3
“26,42 Metformin use was consistent with that of this study; however, other antidiabetic treatments have not yet been clarified.”
Bartolucci, G., Pallecchi, M., Braconi, L., Dei, S., Teodori, E., Lapolla, A., Sartore, G., & Traldi, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010180 · Cited by 3
Ding, J., Li, X., Ge, J., Gong, Y., Zhou, Y., Xiao, J., Yang, Q., Chen, J., & Mao, M. (2022) · Cancer Management and Research · doi:10.2147/cmar.s340334 · Cited by 3
“Epidemiological data show that T2DM is a risk factor for the occurrence, development and prognosis of various tumors, and it has a significant impact on the prognosis of breast cancer, colorectal cancer and gastric cancer.(15,16) The mechanisms are complex, possibly including excessive ROS-formation, oxidative stress,…”
BackgroundДрук, И. В., Semenova, E. V., Логинова, Е. Н., Korennova, O. Y., Анатольевич, С. А., Lyalyukova, E. A., & Nadey, E. V. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-205-9-116-128 · Cited by 4
Maruzen, S., Munesue, S., Okazaki, M., Takada, S., Nakanuma, S., Makino, I., Gong, L., Kohno, S., Takahashi, C., Tajima, H., et al. (2024) · Onco · doi:10.3390/onco4020007 · Cited by 3
“Epidemiological studies have shown that patients with type 2 diabetes receiving metformin have significantly lower carcinogenic and mortality rates than those on other treatments [11–14].”
BackgroundShojaeian, A. (2024) · Journal of Wound Management and Research · doi:10.22467/jwmr.2024.02957 · Cited by 3
“Interestingly, the extensive application of this medication in treating diabetes has been associated with a decreased occurrence of various cancer types, due to its reported influence on inhibiting cancer cell proliferation [13].”
BackgroundChemoprevention strategies in hereditary breast and ovarian cancer syndromes
Barbieri, E., Venturelli, M., Mastrodomenico, L., Piombino, C., Ponzoni, O., Zaniboni, S., Barban, S., Razzaboni, E., Grandi, G., Dominici, M., et al. (2024) · Tumori Journal · doi:10.1177/03008916241274721 · Cited by 3
Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review
Lee, D., Liew, M. S., Fourlanos, S., & Choi, J. (2025) · ANZ Journal of Surgery · doi:10.1111/ans.19405 · Cited by 3
“5,6 A possible explanation for this bene fi t was suggested by an in vitro study of breast cancer cell lines where metformin inhibited cancer cell growth, suppressed the overexpression of human epidermal growth factor receptor 2 and inhibited mammalian target of rapamycin (mTOR).”
McLean, R. C., & Logue, J. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0105-3 · Cited by 3
Nubiola, A., Ferrer, M., & Remolins, I. (2014) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2014.06.001 · Cited by 5
La metformine revisitée et consolidée en 2016 : un point de vue consensuel de l’Afrique à l’Europe
Buysschaert, M., Djrolo, F., Guenou, A., Abodo, J., Lokrou, A., Preumont, V., Buysschaert, B., & Diop, S.-N. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30034-7 · Cited by 4
Augustin, L. S. A., Montagnese, C., Calabrese, I., Porciello, G., Palumbo, E., Vitale, S., & Nishi, S. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65132-2 · Cited by 3
Kato, J., Shirakami, Y., & Shimizu, M. (2019) · Gastrointestinal Disorders · doi:10.3390/gidisord1020023 · Cited by 3
Osipov, M., Semiglazova, Т. Y., Popovich, I. G., Панченко, А. В., Тындык, М. Л., Zabezhinskiy, M., Klimenko, V. V., Стуков, А. Н., & Anisimov, V. N. (2017) · Voprosy Onkologii · doi:10.37469/0507-3758-2017-63-4-650-654 · Cited by 4
Shah, R. R. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.07.003 · Cited by 3
“antihyperglycemic agents, has anticancer properties that favorably influence cancer risk, including that of RCC, and cancer-related outcomes.(6-10) The effect depends on the dose and duration of metformin therapy.”
BackgroundNovel Therapies Metformin: The sweet link between tumor genetics and metabolism?
Nowak, K. L., Eldredge-Hindy, H., & Champ, C. (2014) · Cited by 3
Boffetta, P., & Collatuzzo, G. (2023) · Springer eBooks · doi:10.1007/978-1-4614-6625-3_36-1 · Cited by 2
Lu, Z., Bi, J., Zheng, C., Cui, L., Xia, H., Wan, X., & Chen, Y. H. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.032 · Cited by 2
Metformin: Its salutary effects beyond diabetes mellitus
Sawalha, K., Gautam, N., Sivakumar, K., Paydak, H., & Mehta, J. L. (2025) · Journal of Investigative Medicine · doi:10.1177/10815589251327511 · Cited by 4
“…use of metformin compared with nonuse or use of other diabetes treatment was associated with a reduced risk of all cancers (relative risk (RR): 0.61, 95% CI: 0.54–0.70), 99,100 colorectal cancer (RR: 0.64, 95% CI: 0.54–0.76), 101 Among the meta-analyses, the overall effect estimates were similar.”
InfluentialEmerging Link between Diabetes and Cancer
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2015) · Journal of General and Family Medicine · doi:10.14442/jgfm.16.3_170 · Cited by 2
Self-citation[Research Advance in Anti-lung Cancer Mechanism of Metformin].
Wang, G., Xu, M., & Xie, M. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.02 · Cited by 2
New Association Between Diabetes Mellitus and Pancreatic Cancer
Bakhtiyari, S., Rezaei, M., Shams, Z., Rasouli, B. S., Amirfard, K. D., Sadrabadi, M. S., Gheysarzadeh, A., & Haghani, K. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220118095952 · Cited by 2
Recurrent hypoglycemia in a patient with hepatocellular carcinoma
Satar, S. N. A. W., Norhayati, M. N., & Yaacob, L. H. (2023) · Electronic Journal of General Medicine · doi:10.29333/ejgm/12903 · Cited by 2
Tumor metabolic reprogramming in therapeutic resistance
Siegel, P. M., & Ursini‐Siegel, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00005-x · Cited by 1
Roest, S., Gürgöze, M. T., Cherikh, W. S., Stehlik, J., Boersma, E. H., Zijlstra, F., & Manintveld, O. C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1145996 · Cited by 2
“Recent investigations suggested that metformin reduces the incidence and mortality due to malignancies (26).”
BackgroundTargeting HK2 in Anticancer Therapy
Walczak, K. (2024) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2024.56.008847 · Cited by 1
Wawszczyk, J., Wolan, R., Kapral, M., & Orchel, A. (2025) · Acta Poloniae Pharmaceutica - Drug Research · doi:10.32383/appdr/197350 · Cited by 1
“Clinical trials have shown that patients using metformin have a lower risk of developing malig - nant neoplasms [9].”
Sroor, F. M., Basyouni, W. M., El-Ashrey, M. K., Younis, E. A., & Aly, H. M. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2605013 · Cited by 1
TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches
Callegari, E., Michilli, A., Moshiri, F., Siena, B. D., Gramantieri, L., Negrini, M., & Sabbioni, S. (2026) · BioTech · doi:10.3390/biotech15010009 · Cited by 2
“Metformin, an antidiabetic drug epidemiologically linked to reduced HCC incidence in type 2 diabetic patients [49–51], was evaluated for preventive action in nondiabetic liver https://doi.org/10.3390/biotech15010009 disease.”
InfluentialKong, Y., Gao, X., Che, Y., Li, X. Y., Gong, X., Luan, X., Cui, Z., & Tian, T. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104662 · Cited by 1
Szymczak-Pajor, I., Drzewoski, J., Wenclewska, S., Rogalska, A., & Śliwińska, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104195 · Cited by 1
“In contrast, epidemiological studies have consistently linked metformin use to a reduced overall cancer risk in patients with T2DM [34,35].”
The Molecular Mechanisms of Metformin’s Action on Blood Lipid Profile in Diabetic Patients
Dettlaff‐Pokora, A., & Świerczyński, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104635 · Cited by 1
“Additionally, it has been suggested that the use of metformin in T2D patients was associated with lower risk of incidence of some cancers and mortality [16–18].”
Hiroki, S., Fukasawa, T., Honda, M., & Kawakami, K. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70429 · Cited by 1
“These findings are consistent with meta-analyses of RCTs and with a recent observational study emulating target trials [11, 14], but contrast with earlier observational studies reporting a substantially lower cancer risk among metformin users compared with nonusers [4, 5, 8, 9].”
Mouse Models to Study Metformin Effects in Carcinogenesis
Schneider, A. (2015) · Energy balance and cancer · doi:10.1007/978-3-319-16733-6_13 · Cited by 1
Cancer as a metabolic disease and diabetes as a cancer risk?
Kaňková, K., & Hrstka, R. (2012) · PubMed · Cited by 3
Yendamuri, S. (2014) · The Journal of Clinical and Scientific Research · doi:10.15380/2277-5706.jcsr.13.054 · Cited by 1
Use of Biguanides to Improve Response to Chemotherapy
Sandulache, V. C., Yang, L., & Skinner, H. D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0856-1_1 · Cited by 2
Hormonal and Metabolic Strategies to Overcome Insulin Resistance and Prevent Endometrial Cancer
Kitson, S., & Crosbie, E. J. (2017) · Energy balance and cancer · doi:10.1007/978-3-319-63483-8_10 · Cited by 1
Muhammad, D. D., JAVED, M. H., & Iftikhar, M. (2019) · The Professional Medical Journal · doi:10.29309/tpmj/2019.26.04.2876 · Cited by 1
The use of metformin in the treatment of gastrointestinal cancer
Ткач, С. М. (2021) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2021-3-60 · Cited by 1
Pankreaskarzinom: Risikofaktoren, Hochrisikodefinition und mögliche Screeningmaßnahmen
Obermair, F., Popper, U., Romeder, F., & Rumpold, H. F. (2016) · Wiener klinisches Magazin · doi:10.1007/s00740-016-0107-4 · Cited by 1
Horaţiu-Cristian, P.-V., Bratu, M. R., Stancu, D. M., Antonescu, M., Tudor, D. P., Nan, R., Dragut, R., Rusu, E., Posea, M., & Radulian, G. (2015) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2015-0015 · Cited by 1
“In our study, patients receiving metformin treatment were diagnosed less frequently with cancer, in fact metformin being associated with a decreased risk of cancer in many epidemiological studies [32-35].”
BackgroundPharmacological approaches for correction of thyroid dysfunctions in diabetes mellitus
Shpakov, A. O. (2017) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20176303219 · Cited by 1
Rashid, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-2579-2_25 · Cited by 1
Modeling for the Care of Complex Patients.
Nataraj, N. (2017) · NCSU Libraries Repository (North Carolina State University Libraries) · Cited by 1
Noto, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-4376-5_9 · Cited by 1
Self-citationDiabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response
Hassinger, T. E., Berger, A. C., Christopher, A. N., Knisely, A. T., Mehaffey, J. H., Brenin, D. R., Schroen, A. T., & Showalter, S. L. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.10.043 · Cited by 1
Cybulska, P., & Leitão, M. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_19 · Cited by 1
Lazzeroni, M., & Gandini, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65133-4 · Cited by 1
Heresbach, D., & Pienkowski, P. (2014) · Acta Endoscopica · doi:10.1007/s10190-014-0411-z · Cited by 1
Metadata
- Authors
- Noto, H., Goto, A., Tsujimoto, T., & Noda, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- Corresponding author
- Noto, Hiroshi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-20
- Volume
- 7
- Issue
- 3
- Pages
- e33411
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3308971
- OpenAlex
- W2040608814
- Cited by
- 566
- References
- 106
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 20 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 41 · 2019: 38 · 2018: 28 · 2017: 50 · 2016: 60 · 2015: 57 · 2014: 60 · 2013: 65 · 2012: 25
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, diabetes mellitus, cancer risk, cancer mortality, cancer incidence, colorectal cancer, hepatocellular carcinoma, lung cancer, chemoprevention
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.